In this week’s View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH).

The ACC has launched a new program, Transform HF Care: New Horizons in Treatment, to educate clinicians on the latest advances, medications and interventions emerging in heart failure (HF) management ...

An experimental wrist-worn device was found to predict troponin-I and obstructed arteries with 90% accuracy in five minutes, according to research being presented at the American College of Cardiology ...

In this episode, Barbara Srichai-Parsia, MD, FACC, Ron Blankstein, MD, FACC and Roosha Parikh, MD, FACC, will focus on the value of fractional flow reserve – computed tomography (FFR-CT) and emerging ...

ACC chapter members, find out more about the legislator practice visit program.

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

The DAPT SHOCK AMI trial is the first major study to evaluate antiplatelet therapy specifically in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI). It compares initial ...

A new ACC Scientific Statement on Inflammation and Cardiovascular Disease (CVD) highlights new groundbreaking research linking inflammation atherosclerotic cardiovascular disease (ASCVD) and provides ...

The Global Heart Attack Treatment Initiative (GHATI) is dedicated to collaborating, collecting and sharing data, and utilizing tools to improve acute myocardial infarction (AMI) care for your MI ...

Cardiovascular diseases (CVD) remain the leading cause of disease burden , causing one in three deaths worldwide as a result of population growth, population aging and exposure to a broad range of ...

Oral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the ...

In this week’s View, Dr. Eagle looks at the net benefit of intensive blood pressure control between fewer cardiovascular and more adverse events. He then explores non-atherothrombotic myocardial ...